Stimulated adverse drug reaction reporting in pharmacovigilance: Indian perspectives-Reference-Cited by-同舟云学术

Stimulated adverse drug reaction reporting in pharmacovigilance: Indian perspectives

Published:2021-06-01 Issue:2 Volume:2 Page:13-18
ISSN:2582-7235
Container-title:Journal of Pharmacovigilance and Drug Research
language:
Short-container-title:jpadr

Author:

Thota Anusha^ORCID,Sarkar Siddharth,Guptha Snehil,Thota Prasad

Abstract

Introduction: The voluntary reporting of adverse drug reactions requires continuous stimulation and motivation. Methods: It is achieved by the development of a positive approach towards pharmacovigilance among healthcare professionals so that adverse reaction reporting becomes an accepted and understood routine. Results: In summary, the various strategies developed and made available in India to stimulate reporting, promotion, educational interventions/ awareness program/academics, hospital-based ADRs reporting, establish a culture of reporting. Conclusions: These exclusive strategies progress the reporting rate in India by altering the mindset of healthcare professionals, undergraduates, and consumers towards safety reporting.

Publisher

Global Pharmacovigilance Society

Reference27 articles.

1. Arici, M. A., Gelal, A., Demiral, Y., & Tuncok, Y. (2015). Short and long-term impact of pharmacovigilance training on the pharmacovigilance knowledge of medical students. Indian journal of pharmacology, 47(4), 436–439.

2. Cassels A. K. (2007). The media-medicine mix: quality concerns in medical reporting. Open medicine: a peer-reviewed, independent, open-access journal, 1(1), e52–e54.

3. Cassels, A., Hughes, M. A., Cole, C., Mintzes, B., Lexchin, J., & McCormack, J. P. (2003). Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne, 168(9), 1133–1137.

4. Dorsey, E. R., Rabbani, A., Gallagher, S. A., Conti, R. M., & Alexander, G. C. (2010). Impact of FDA black box advisory on antipsychotic medication use. Archives of internal medicine, 170(1), 96–103.

5. Edwards, I. R., & Lindquist, M. (2011). Social media and networks in pharmacovigilance: boon or bane? Drug safety, 34(4), 267–271.